DRG 394 Overview

DRG 394 covers inpatient cases involving other digestive system diagnoses with a Complication or Comorbidity. This Diagnosis-Related Group includes a range of non-specific gastrointestinal conditions that incur additional complexity due to comorbid conditions or complications. It matters for Medicare payment because the presence of a Complication or Comorbidity adjusts relative resource use and affects reimbursement levels under the Medicare Severity Diagnosis-Related Group system. Accurate coding of the primary diagnosis and associated Complication or Comorbidity determines the appropriate payment grouping.

Across commercial payers the rate range runs roughly from $9K up to $34K, with the widest spread observed between BCBS (as low as $370/$1.2K in lower percentiles to $25K max) and Anthem (max $34K). Reference the payer table and the chart below for percentile detail and payer-specific distributions. National commercial benchmarks show variation by payer, with Aetna, Cigna, Anthem, and BCBS reporting different median and upper-quartile values.

The CMS 2023 data represent national Medicare fee-for-service inpatient payments published under the CMS Provider Utilization and Payment Data program. The table below reports average total payment ($9.1k), average submitted covered charges ($44.6k), average Medicare payment amount ($7.0k), and total discharges (30.3k).

• Acute intervention trials evaluating optimized perioperative or inpatient care bundles for patients admitted with complicated or symptomatic non-specific digestive diagnoses (for example severe gastritis, acute pancreatitis without severe organ failure, or complex biliary colic). These studies enroll patients during the inpatient stay to test protocols that may include early imaging and risk stratification, standardized IV fluid and electrolyte management, and criteria-driven timing for endoscopy or minimally invasive procedures. Results are relevant to providers for improving short-term clinical outcomes and to payers because reductions in length of stay, avoidance of ICU transfers, and fewer procedure-related complications can lower inpatient costs for this heterogeneous DRG group.
• Comparative effectiveness studies comparing diagnostic and therapeutic strategies for subgroups within the DRG, such as outpatient versus inpatient observation pathways for suspected but unconfirmed acute digestive conditions, or early endoscopic intervention versus conservative management for select presentations. These trials typically focus on patients with moderate illness severity and comorbidities that place them at risk for CC-level complications, aiming to identify which approaches best balance clinical outcomes, readmission risk, and resource use. Payers and hospital leaders use this evidence to design care pathways and utilization criteria that target appropriate admissions, reduce unnecessary procedures, and optimize reimbursement margins while maintaining patient safety.
• Post-discharge outcomes and care-transition research assessing readmission prevention, medication adherence, nutrition support, and outpatient follow-up effectiveness among patients discharged after treatment for complex digestive conditions (for example ongoing symptom control after peptic ulcer disease with bleeding history or management of chronic pancreatitis exacerbations). These observational cohort studies and pragmatic trials enroll patients at discharge and measure 30- and 90-day readmissions, emergency visits, and functional status, often integrating case management or telehealth follow-up arms. Findings guide discharge planning, allocation of transitional care resources, and payer investments in outpatient programs that can reduce costly readmissions and downstream utilization for this DRG population.